{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:44:04Z","timestamp":1781196244482,"version":"3.54.1"},"reference-count":112,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.<\/jats:p>","DOI":"10.3390\/ijms21093377","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T10:01:18Z","timestamp":1589191278000},"page":"3377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment"],"prefix":"10.3390","volume":"21","author":[{"given":"Marcella","family":"Prete","sequence":"first","affiliation":[{"name":"Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Favoino","sequence":"additional","affiliation":[{"name":"Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Catacchio","sequence":"additional","affiliation":[{"name":"Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-1940","authenticated-orcid":false,"given":"Vito","family":"Racanelli","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-4244","authenticated-orcid":false,"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[{"name":"Systemic Rheumatic and Autoimmune Diseases Unit, Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, I-70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,10]]},"reference":[{"key":"ref_1","first-page":"536","article-title":"Severe acute respiratory syndrome-related coronavirus\u2014The species and its viruses\u2014A statement of the Coronavirus Study Group","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"bioRxiv"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30419-0","article-title":"A distinct name is needed for the new coronavirus","volume":"395","author":"Jiang","year":"2020","journal-title":"Lancet"},{"key":"ref_3","unstructured":"De Groot, R.J., Baker, S.C., Baric, R., Enjuanes, L., Gorbalenya, A.E., Holmes, K.V., Perlman, S., Poon, L., Rottier, P.J.M., and Talbot, P.J. (2011). Family Coronaviridae. Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses, Academic Press, Ltd."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11297","DOI":"10.1128\/JVI.01498-14","article-title":"Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat","volume":"88","author":"Corman","year":"2014","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(03)13967-0","article-title":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome","volume":"362","author":"Kuiken","year":"2003","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/JVI.01244-13","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group","volume":"87","author":"Baker","year":"2013","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","article-title":"ACE2: From vasopeptidase to SARS virus receptor","volume":"25","author":"Turner","year":"2004","journal-title":"Trends. Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Borges do Nascimento, I., Cacic, N., Abdulazeem, H.M., von Groote, T.C., Jayarajah, U., Weerasekara, I., Esfahani, M.A., Civile, V.T., Marusic, A., and Jeroncic, A. (2020). Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040941"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., and Hui, D.S.C. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2002032"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rothan, H.A., and Byrareddy, S.N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun.","DOI":"10.1016\/j.jaut.2020.102433"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., and Xiong, Y. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.","DOI":"10.1001\/jama.2020.1585"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA.","DOI":"10.1001\/jama.2020.2648"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jth.14821","article-title":"The versatile heparin in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rodriguez-Morales, A.J., Cardona-Ospina, J.A., Gutierrez-Ocampo, E., Villamizar-Pena, R., Holguin-Rivera, Y., Escalera-Antezana, J.P., varado-Arnez, L.E., Bonilla-Aldana, D.K., Franco-Paredes, C., and Henao-Martinez, A.F. (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel. Med. Infect. Dis.","DOI":"10.1016\/j.tmaid.2020.101623"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Baden, L.R., and Rubin, E.J. (2020). Covid-19\u2014The Search for Effective Therapy. N. Engl. J. Med.","DOI":"10.1056\/NEJMe2005477"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tian, S., Hu, W., Niu, L., Liu, H., Xu, H., and Xiao, S.Y. (2020). Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J. Thorac. Oncol.","DOI":"10.20944\/preprints202002.0220.v2"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0046-8177(03)00367-8","article-title":"Lung pathology of severe acute respiratory syndrome (SARS): A study of 8 autopsy cases from Singapore","volume":"34","author":"Franks","year":"2003","journal-title":"Hum. Pathol."},{"key":"ref_28","first-page":"1","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"Carmi","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2648","DOI":"10.1097\/MD.0000000000002648","article-title":"Antiphospholipids Syndrome Complicated by a Systemic Capillary Leak-Like Syndrome Treated With Steroids and Intravenous Immunoglobulins: A Case Report","volume":"95","author":"Prete","year":"2016","journal-title":"Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/imr.12839","article-title":"Inflammasomes contributing to inflammation in arthritis","volume":"294","author":"Spel","year":"2020","journal-title":"Immunol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3899\/jrheum.170955","article-title":"Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort","volume":"45","author":"Ruscitti","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fped.2019.00244","article-title":"Aetiological Significance of Infectious Stimuli in Kawasaki Disease","volume":"7","author":"Nakamura","year":"2019","journal-title":"Front. Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S1047951111001314","article-title":"Capillary leak leading to shock in Kawasaki disease without myocardial dysfunction","volume":"22","author":"Natterer","year":"2012","journal-title":"Cardiol. Young"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., and Vieira, V.E. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents.","DOI":"10.1101\/2020.03.16.20037135"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","article-title":"Insights from nanomedicine into chloroquine efficacy against COVID-19","volume":"15","author":"Hu","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhou, D., Dai, S.M., and Tong, Q. (2020). COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemother.","DOI":"10.1093\/jac\/dkaa114"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell. Discov."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Michot, J.M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., and Netzer, F. (2020). Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: A case report. Ann. Oncol.","DOI":"10.1016\/j.annonc.2020.03.300"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","article-title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD","volume":"79","author":"Mihai","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Xie, M., and Chen, Q. (2020). Insight into 2019 novel coronavirus\u2014An updated intrim review and lessons from SARS-CoV and MERS-CoV. Int. J. Infect. Dis.","DOI":"10.1016\/j.ijid.2020.03.071"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ferrey, A.J., Choi, G., Hanna, R.M., Chang, Y., Tantisattamo, E., Ivaturi, K., Park, E., Nguyen, L., Wang, B., and Tonthat, S. (2020). A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. Am. J. Nephrol., 1\u20136.","DOI":"10.1159\/000507417"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wu, Z., Li, J.W., Zhao, H., and Wang, G.Q. (2020). The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents.","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1128\/JVI.00527-07","article-title":"Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome","volume":"81","author":"Cameron","year":"2007","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"130","author":"Channappanavar","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102434","DOI":"10.1016\/j.jaut.2020.102434","article-title":"The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China","volume":"109","author":"Yang","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Li, J., Teng, Y., Sun, H., Tian, G., He, L., Li, P., Chen, Y., Guo, Y., and Li, J. (2019). Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV. Viruses, 11.","DOI":"10.3390\/v11010039"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Caso, F., Costa, L., Ruscitti, P., Navarini, L., Del, P.A., Giacomelli, R., and Scarpa, R. (2020). Could Sars-coronavirus-2 trigger autoimmune and\/or autoinflammatory mechanisms in genetically predisposed subjects?. Autoimmun. Rev.","DOI":"10.1016\/j.autrev.2020.102524"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Prete, M., Favoino, E., Catacchio, G., Racanelli, V., and Perosa, F. (2020). SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?. Autoimmun. Rev.","DOI":"10.1016\/j.autrev.2020.102559"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fimmu.2018.01308","article-title":"What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review","volume":"9","author":"Jones","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014An expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12026-016-8828-4","article-title":"An idiopathic thrombocytopenic purpura with polyneuropathy","volume":"65","author":"Katchan","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2009.12.004","article-title":"Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin","volume":"9","author":"Galeotti","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_61","first-page":"293","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: Revisiting the role of intravenous immmunoglobulins","volume":"15","author":"Chapman","year":"2013","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s10875-010-9408-3","article-title":"Intravenous immunoglobulin treatment in multifocal motor neuropathy","volume":"30","author":"Cats","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"ref_63","first-page":"754","article-title":"The Efficacy of Intravenous Immunoglobulin in Guillain-Barre Syndrome: The Experience of a Tertiary Medical Center","volume":"20","author":"Shalem","year":"2018","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e008316","DOI":"10.1136\/bmjopen-2015-008316","article-title":"Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation","volume":"5","author":"Cowan","year":"2015","journal-title":"BMJ Open"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.autrev.2004.10.004","article-title":"Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia","volume":"4","author":"Mouthon","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"ref_66","first-page":"206","article-title":"Bench-to-bedside review: Immunoglobulin therapy for sepsis\u2014Biological plausibility from a critical care perspective","volume":"16","author":"Spencer","year":"2012","journal-title":"Crit. Care"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12026-014-8571-7","article-title":"Intravenous immune globulins (IVIg) treatment for organizing pneumonia in a selective IgG immune deficiency state","volume":"60","author":"Gueta","year":"2014","journal-title":"Immunol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-6143.2010.03400.x","article-title":"Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients","volume":"11","author":"Jordan","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.autrev.2015.04.003","article-title":"The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis","volume":"14","author":"Khattri","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2005.09.002","article-title":"Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus","volume":"5","author":"Sherer","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.autrev.2018.10.002","article-title":"Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus","volume":"18","author":"Martinez","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0961203319883680","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: A single-center experience with 63 patients","volume":"28","author":"Martinez","year":"2019","journal-title":"Lupus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5045\/br.2017.52.2.119","article-title":"Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children","volume":"52","author":"Kim","year":"2017","journal-title":"Blood Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Baig, S., and Paik, J.J. (2020). Inflammatory muscle disease\u2014An update. Best Pract. Res. Clin. Rheumatol.","DOI":"10.1016\/j.berh.2019.101484"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2015.11.009","article-title":"Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature","volume":"15","author":"Tenti","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjmed.2014.08.015","article-title":"High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease)","volume":"128","author":"Xie","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.autrev.2015.03.005","article-title":"Granulomatosis with polyangiitis and intravenous immunoglobulins: A case series and review of the literature","volume":"14","author":"Guidelli","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2045-7022-4-38","article-title":"High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis","volume":"4","author":"Tsurikisawa","year":"2014","journal-title":"Clin. Transl. Allergy"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/187152812803251024","article-title":"Intravenous immunoglobulin as a potential therapy for refractory urticaria\u2014A review","volume":"11","author":"Watkins","year":"2012","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.autrev.2019.02.005","article-title":"Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy","volume":"18","author":"Buonavoglia","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e12854","DOI":"10.1111\/dth.12854","article-title":"Intravenous immunoglobulin treatment: Where do dermatologists stand?","volume":"32","author":"Emre","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_84","first-page":"e131","article-title":"Efficacy of intravenous immunoglobulins for laryngopharyngeal lesions and upper airway obstruction in epidermolysis bullosa acquisita","volume":"34","author":"Honda","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000502818","article-title":"A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate\/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations","volume":"81","author":"Karelis","year":"2019","journal-title":"Eur. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liu, X., Treister, R., Lang, M., and Oaklander, A.L. (2018). IVIg for apparently autoimmune small-fiber polyneuropathy: First analysis of efficacy and safety. Ther. Adv. Neurol. Disord., 11.","DOI":"10.1177\/1756285617744484"},{"key":"ref_87","first-page":"CD008557","article-title":"Intravenous immunoglobulins for epilepsy","volume":"12","author":"Geng","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1532\/IJH97.06222","article-title":"Intravenous immunoglobulin therapy for acquired coagulation inhibitors: A critical review","volume":"85","author":"Yamamoto","year":"2007","journal-title":"Int. J. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.anai.2015.11.017","article-title":"Immunoglobulin replacement for selective IgM immunodeficiency, bronchiectasis, and asthma","volume":"116","author":"Goldstein","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jri.2019.06.001","article-title":"Treatment with intravenous immunoglobulin in patients with recurrent pregnancy loss: An update","volume":"133","author":"Christiansen","year":"2019","journal-title":"J. Reprod. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","article-title":"In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations\u2014A potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases","volume":"12","author":"Krause","year":"2002","journal-title":"Transfus. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Shoenfeld, Y. (2020). Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun. Rev.","DOI":"10.1016\/j.autrev.2020.102538"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12098-015-1877-1","article-title":"Macrophage Activation Syndrome","volume":"83","author":"Sen","year":"2016","journal-title":"Indian J. Pediatr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea","volume":"374","author":"Van","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Jawhara, S. (2020). Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072272"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Bloch, E.M., Shoham, S., Casadevall, A., Sachais, B.S., Shaz, B., Winters, J.L., Chan, P., Wong, K.C., Leung, C.B., and Cheng, G. (2020). Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Investig., 138745.","DOI":"10.1172\/JCI138745"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., and Xing, L. (2020). Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA.","DOI":"10.1001\/jama.2020.4783"},{"key":"ref_103","first-page":"1","article-title":"COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","volume":"18","author":"Dhama","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s11427-017-9189-3","article-title":"Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses","volume":"60","author":"Zeng","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Ter Meulen, J., van den Brink, E.N., Poon, L.L., Marissen, W.E., Leung, C.S., Cox, F., Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., and van Deventer, E. (2006). Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030237"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Thanh Le, T., Andreadakis, Z., Kumar, A., Gomez Roman, R., Tollefsen, S., Saville, M., and Mayhew, S. (2020). The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov.","DOI":"10.1038\/d41573-020-00073-5"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/science.368.6486.14","article-title":"Vaccine designers take first shots at COVID-19","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA Vaccines for Infectious Diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_111","first-page":"243","article-title":"Recent Advances in Lentiviral Vaccines for HIV-1 Infection","volume":"7","author":"Norton","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: Where are we?","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Rev. Vaccines"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:27:29Z","timestamp":1760174849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,10]]},"references-count":112,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21093377"],"URL":"https:\/\/doi.org\/10.3390\/ijms21093377","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,10]]}}}